PDCD1 and neoplasm: ICB, the including PD-1/PD-L1 blockade, can produce synergistic antitumor effects, and significantly improve ID8 tumor-bearing mouse survival, when combined with chemotherapy, such as paclitaxel, which is able to upregulate PD-L1 expression in tumor cells [151], or trabectedin [152].